November 29, 2022
  • AstraZeneca PLC announced it will acquire Neogene Therapeutics Inc. in a deal worth up to $320 million, growing the company’s oncology portfolio. The transaction is expected to close in the first quarter of 2023, subject to customary closing conditions and regulatory clearances. Upon completion of the transaction, Neogene will operate as a wholly owned subsidiary, with operations in Amsterdam, The Netherlands, and Santa Monica, California. (Press release here)